Elixinol Wellness (AU:EXL)
ASX:EXL
Want to see AU:EXL full AI Analyst Report?
Top Page
Elixinol Wellness
(Sydney:EXL)
Select Model
Select Model
Rating:49Neutral
Price Target:
AU$0.02
▲(50.00% Upside)
Action:Reiterated
Date:05/16/26
The score is held down primarily by weak financial performance—ongoing losses, persistent cash burn, and some balance-sheet deterioration in 2025. Offsetting this are improved operational signals from the earnings call (cost reductions and Q4 EBITDA/underlying cash-flow improvement) and supportive technical momentum, though the stock appears overbought (high RSI) and valuation remains constrained by negative earnings.
Positive Factors
Higher‑margin D2C / e‑commerce mix
A sustained shift to higher‑margin direct‑to‑consumer sales improves gross margins and cash predictability long term. Digital sales growth (and repeat D2C relationships) reduces dependence on low‑margin wholesale and gives scalable customer economics if acquisition and retention stay efficient.
Negative Factors
Persistent negative operating cash flow
Ongoing negative OCF and FCF mean the business cannot self‑fund growth or working capital and will remain reliant on external financing. Persistent cash burn limits flexibility, raises refinancing risk if markets tighten, and constrains investment in marketing, R&D, or distribution needed to scale revenues.
Read all positive and negative factors
Positive Factors
Negative Factors
Higher‑margin D2C / e‑commerce mix
A sustained shift to higher‑margin direct‑to‑consumer sales improves gross margins and cash predictability long term. Digital sales growth (and repeat D2C relationships) reduces dependence on low‑margin wholesale and gives scalable customer economics if acquisition and retention stay efficient.
Read all positive factors
Elixinol Wellness (EXL) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$3.73M
Dividend YieldN/A
Average Volume (3M)554.74K
Price to Earnings (P/E)―
Beta (1Y)-0.73
Revenue Growth3.64%
EPS Growth-23.56%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding413,987,730
10 Day Avg. Volume558,811
30 Day Avg. Volume554,744
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.15
P/FCF Ratio-0.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Elixinol Wellness Business Overview & Revenue Model
Company Description
Elixinol Wellness Limited, through its subsidiaries, manufactures and distributes hemp derived nutraceuticals, cosmetics, and food products under the Elixinol and Hemp Foods Australia brands in the Americas, Europe, and Australia. It offers hemp d...
How the Company Makes Money
Elixinol Wellness makes money primarily by selling branded wellness products to customers, generating revenue when products are purchased through its direct-to-consumer online channels and, where applicable, through wholesale or retail distributio...
Elixinol Wellness Earnings Call Summary
Earnings Call Date:Feb 12, 2026
(Q4-2025)
| Next Earnings Date:Aug 27, 2026
Earnings Call Sentiment Positive
The call communicated meaningful operational progress: a clear shift to higher-margin channels (e-commerce up to 38%), significant cost structure reduction (~30% in Q4 vs prior year), Q4 profitability and positive operating cash flow, strong D2C momentum (Healthy Chef e-commerce +42% YoY) and product innovation poised to capture market trends. However, challenges remain including modest full-year revenue growth (3.6% YoY), a small absolute revenue base (~$15.5M), supermarket channel pressures for niche SKUs, and regulatory uncertainty in the U.S. CBD business. On balance, the operational improvements and trajectory toward sustainable profitability outweigh the outstanding strategic and market risks, but execution and regulatory clarity will be important near-term drivers.Positive Updates
Q4 Revenue Growth and Strong Exit Run-Rate
Q4 FY25 revenue of $4.1M, up 9.5% quarter-on-quarter, delivering a strong exit run-rate into FY26 and demonstrating seasonal rebound in the business.
Negative Updates
Modest Full-Year Top-Line Growth
FY25 revenue growth was modest at 3.6% year-over-year ($15.5M), indicating limited top-line expansion despite improvements in mix and margins.
Read all updates
Q4-2025 Updates
Positive
Negative
Q4 Revenue Growth and Strong Exit Run-Rate
Q4 FY25 revenue of $4.1M, up 9.5% quarter-on-quarter, delivering a strong exit run-rate into FY26 and demonstrating seasonal rebound in the business.
Read all positive updates
Company Guidance
Management guided FY26 around four pillars — operational momentum, cost efficiency, building a growth foundation and targeted M&A — with the aim of maintaining a structurally lower OpEx run‑rate after cutting the operating cost base by ~30% in Q4 vs Q4 FY24 and delivering Q4 positive EBITDA (slightly better than break‑even) and positive underlying operating cash flow; they completed a two‑tranche $2.5m capital raise and will review capital management at the May AGM. The company will prioritize higher‑margin D2C and e‑commerce (e‑commerce grew from 21% to 38% of revenue in 2025; Healthy Chef e‑commerce +42% YoY in Q4) while reducing low‑margin bulk (from 24% to 14%), leveraging FY25 revenue of $15.5m and a Q4 exit run‑rate of $4.1m (quarterly revenue ranged ~$3–4m) with contracted hemp volumes up for 2026. Management also signalled near‑term actions — pursuing value‑accretive acquisitions, keeping U.S. CBD options open pending regulatory clarity in 2–3 months, and driving product launches (Healthy Chef Metabolic Burn and protein water, plus Mt Elephant NPD into Coles in May) to capture large market opportunities (Australia wellness ~$160bn today to >$300bn by 2033 at ~7% growth, functional foods ~$10.5bn, protein market to $1.1bn by 2034) and narrow the current valuation gap (~0.3x revenue vs peers 1–1.5x).Elixinol Wellness Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
46
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 15.50M | 14.96M | 8.27M | 7.05M | 9.34M |
| Gross Profit | 752.00K | 5.36M | -1.80M | -3.27M | -6.25M |
| EBITDA | -4.11M | -4.01M | -6.81M | -9.28M | -15.51M |
| Net Income | -5.50M | -1.72M | -7.51M | -10.57M | -17.02M |
Balance Sheet | |||||
| Total Assets | 15.96M | 18.45M | 11.71M | 13.48M | 25.33M |
| Cash, Cash Equivalents and Short-Term Investments | 1.41M | 1.08M | 708.00K | 2.86M | 12.65M |
| Total Debt | 3.95M | 1.94M | 1.26M | 1.83M | 2.71M |
| Total Liabilities | 8.51M | 8.42M | 5.25M | 4.33M | 6.25M |
| Stockholders Equity | 7.45M | 10.03M | 6.46M | 9.16M | 19.08M |
Cash Flow | |||||
| Free Cash Flow | -3.28M | -3.53M | -2.77M | -8.16M | -14.36M |
| Operating Cash Flow | -3.21M | -3.47M | -2.76M | -8.15M | -14.07M |
| Investing Cash Flow | -216.00K | -66.00K | -1.04M | -869.00K | 172.00K |
| Financing Cash Flow | 3.65M | 3.92M | 1.61M | -757.00K | -1.16M |
Elixinol Wellness Technical Analysis
Positive
0.01
Price Trends
0.01
Positive
0.01
Positive
Market Momentum
<0.01
Negative
74.57
Negative
52.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EXL, the sentiment is Positive. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 74.57 is Negative, neither overbought nor oversold. The STOCH value of 52.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:EXL.
Elixinol Wellness Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | AU$138.83M | 6.43 | 19.15% | 4.33% | 17.31% | 17.99% | |
57 Neutral | AU$23.86M | -12.06 | 1.66% | 3.28% | 2.11% | -64.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$29.97M | -21.01 | 10.83% | ― | 15.21% | -141.82% | |
49 Neutral | AU$3.73M | -0.30 | -76.30% | ― | 3.64% | -23.56% | |
43 Neutral | AU$18.57M | -2.29 | 4388.00% | ― | -53.90% | 57.52% | |
39 Underperform | AU$8.13M | 0.07 | 93.89% | ― | -29.95% | ― |
* Healthcare Sector Average
AU:EXL
Elixinol Wellness
0.02
<0.01
25.00%
AU:CAN
Cann Group
0.01
>-0.01
-33.33%
AU:VLS
Vita Life Sciences Limited
2.56
0.86
50.41%
AU:LGP
Little Green Pharma Ltd.
0.10
>-0.01
-5.00%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-33.33%
AU:VIT
Cronos Australia Ltd.
0.04
-0.03
-46.15%
Elixinol Wellness Corporate Events
Elixinol Wellness Sets Virtual FY25 AGM and Moves to Electronic Meeting Materials
Apr 24, 2026
Elixinol Wellness has scheduled its FY25 Annual General Meeting for 27 May 2026 at 10:00am AEST, to be held virtually via an online webinar platform. The company is adopting an electronic delivery model for AGM materials in line with changes to th...
Elixinol boosts margins and cash flow as Healthy Chef drives growth
Apr 21, 2026
Elixinol Wellness reported Q1 FY26 revenue of $3.5 million, stable year on year in what it describes as its seasonally weakest quarter, while shifting its mix toward higher-margin products and channels. Gross margin rose to 45% from 37% a year ear...
Elixinol Wellness Moves to Cut Registry Costs With Small Parcel Share Sale
Apr 20, 2026
Elixinol Wellness has launched a small parcel sale facility to enable shareholders holding less than a marketable parcel of its shares, defined as under $500 in value, to sell their stakes without paying brokerage or related transaction costs. The...
Elixinol Wellness Names New Joint Company Secretaries to Bolster Governance
Apr 13, 2026
Elixinol Wellness has appointed Ms Mariia Skorikova and Mr Tony Di Pietro as joint company secretaries, effective immediately, replacing Ms Melanie Leydin. The pair will be responsible for communications with the ASX on listing rule matters, bring...
Elixinol Wellness Sets May 2026 AGM and Opens Director Nomination Window
Mar 31, 2026
Elixinol Wellness has scheduled its Annual General Meeting for 27 May 2026, where the re-election of directors will be on the agenda and further details will be provided to shareholders in a forthcoming notice. The company has also set 8 April 202...
Elixinol Wellness Switches Share Registry Provider to Boardroom
Mar 30, 2026
Elixinol Wellness has announced a change to its share registry management provider, moving these services from Automic Group to Boardroom Pty Limited. Automic Group will cease its role at the close of business on 2 April 2026, with Boardroom assum...
Elixinol Wellness Corrects Director Interest Notice and Tightens Disclosure Controls
Mar 10, 2026
Elixinol Wellness has corrected a previously lodged director’s interest notice after discovering that listed options held by chair Gavin Evans were omitted due to an administrative oversight. The company has filed an updated notice reflectin...
Elixinol Wellness Builds Vertically Integrated Nutrition and Wellness Platform
Feb 27, 2026
Elixinol Wellness is positioning itself as a sustainable nutrition and wellness player with vertically integrated operations in Australia and the U.S., spanning production, manufacturing and distribution. Its brands, including The Healthy Chef, He...
Elixinol Wellness files updated corporate governance statement and Appendix 4G
Feb 27, 2026
Elixinol Wellness has lodged its latest corporate governance statement for the financial year ended 31 December 2025, confirming that the statement is current as of 27 February 2026 and has been approved by the board. The company has opted to publ...
Elixinol Wellness Revenue Edges Higher as Losses Deepen and Net Tangible Assets Turn Negative
Feb 27, 2026
Elixinol Wellness Limited reported a 3.6% rise in revenue to $15.5 million for the year ended 31 December 2025, but its net loss attributable to owners widened sharply to $5.5 million, a 219.4% increase from the prior year. Basic and diluted loss ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.